SONJA F. BIVINS, Magistrate Judge.
This case is before the Court on Plaintiff Vascular Ventures, LLC's Motion to Remand (Doc. 7), Defendant American Vascular Access, LLC's Motion to Transfer (Doc. 2), the "AVA Affiliates" and "Nominal" Defendants'
Plaintiff Vascular Ventures, LLC ("Vascular Ventures") commenced this action in the Circuit Court of Mobile County, Alabama on August 9, 2016, against Defendants American Vascular Access, LLC ("American Vascular"), Janet R. Dees ("Dees"), the AVA Affiliates Defendants, the Nominal Defendants, and various fictitious defendants. (Doc. 1-2 at 2-3). In the complaint, Plaintiff alleges claims against Defendants American Vascular and Dees for Breach of Contract (Count One), Negligent/Reckless Misrepresentation (Count Two), Promissory Fraud (Count Three), Fraudulent Suppression (Count Four), and Fraud in the Inducement (Count Five); against Defendants American Vascular, Dees, and the AVA Affiliates for Conspiracy (Count Six); and against Defendants AVA Affiliates for Intentional Interference with a Contractual Relation (Count Seven) and Intentional Interference with a Business Relationship (Count Eight).
On September 12, 2016, Defendant American Vascular filed a Notice of Removal pursuant to 28 U.S.C. §§ 1441 and 1446 on the basis of diversity jurisdiction. (Doc. 1). On September 12, 2016, Defendant American Vascular filed a Motion to Transfer this action to the Middle District of Florida pursuant to 28 U.S.C. § 1404(a) on the grounds of forum non conveniens and the parties' agreed forum under a forum selection clause. (Doc. 2). On September 12, 2016, the AVA Affiliates and the Nominal Defendants filed a Rule 12(b)(2) Motion to Dismiss for lack of personal jurisdiction. (Doc. 3). On September 12, 2016, Defendants American Vascular and Dees filed a Rule 12(b)(6) Motion to Dismiss for failure to state a claim. (Doc. 4). On September 30, 2016, Plaintiff Vascular Ventures filed a Motion to Remand this action to state court alleging that Defendant American Vascular did not meet its burden of establishing diversity jurisdiction because it failed to adequately establish the requisite amount in controversy. (Doc. 7 at 2). These motions have been fully briefed and are now ready for resolution.
As set forth above, this action was removed by Defendant American Vascular pursuant to 28 U.S.C. §§ 1441 and 1446 on the basis of diversity jurisdiction under 28 U.S.C. § 1332. (Doc. 1). Title 28 U.S.C. § 1441(a) provides, in relevant part:
In addition, 28 U.S.C. § 1446(b) provides in part:
It is well established that, "[i]n a removal action, the party asserting jurisdiction has the burden of establishing proof of jurisdiction by a preponderance of the evidence."
Where the alleged basis for federal jurisdiction is diversity under 28 U.S.C. § 1332, the removing defendant has the burden of demonstrating that there is (1) complete diversity of citizenship and (2) an amount-in-controversy greater than $75,000.
With respect to the amount in controversy requirement, where the plaintiff "has not pled a specific amount of damages, the removing defendant must prove by a preponderance of the evidence that the amount in controversy exceeds the jurisdictional requirement."
In the complaint in this case, Plaintiff seeks unspecified compensatory and punitive damages, as well as equitable relief, for Defendants' alleged breach of contract and intentional torts (including fraud, conspiracy, and intentional interference with contractual and business relationships) arising out of a joint business venture in which Defendants allegedly failed to fulfill their obligations to offer Plaintiff and its member doctors the opportunity to participate in future joint investment ventures.
The evidence shows that on September 12, 2016, Defendant Janet Dees submitted an affidavit in which she attested that she is the President of Defendant American Vascular Access, LLC, whose affiliates include the Defendant AVA Affiliates, and that she is a member of Defendant American Vascular, as well as each of the Defendant AVA Affiliates and the Nominal Defendants. (Doc. 1-1 at 2-5). Defendant Dees attested that, as a result of the AVA Affiliates' investments in the Nominal Defendants, the AVA Affiliates have received more than $750,000 in distributed earnings or dividends, and 10% of those earnings or dividends received from their investments would exceed $75,000. (
Defendant Dees also submitted a supplemental affidavit on October 17, 2016, in which she further attested that she is the manager of the Nominal Defendants Columbus Vascular Center, LLC; Douglas Vascular Center, LLC; Duval Vascular Center, LLC; Gateway Vascular Center, LLC; and Newnan Vascular Center, LLC, and she was the former manager and a member of AVA Affiliates Defendant Sarasota Holdings, LLC. (Doc. 19 at 2). Defendant Dees attested that, given her positions in these companies, as well as her prior experience and training in the industry as a dialysis nurse, she is familiar with the industry-wide accepted valuation methods for vascular centers and has applied those valuation tools to develop, buy, and sell centers for approximately ten years. (
In its Motion to Remand, Plaintiff argues that Dees' testimony is vague and speculative and does not take into account whether a profit has been realized by each entity. (Doc. 7 at 9). The Court disagrees. Having carefully reviewed the evidence at issue, the Court finds that Defendant Dees' affidavit testimony is a reasonable estimate of the actual value of the contested entities and Plaintiff's claimed 10% interest.
In addition, as stated above, Plaintiff seeks punitive damages in this case against multiple defendants for intentional torts including fraud, conspiracy, and tortious interference with contractual and business relationships. "Punitive damages must be considered when determining the jurisdictional amount in controversy in diversity cases."
Having considered the allegations in Plaintiff's complaint, as well as Defendant Dee's affidavit testimony concerning the reasonable estimate of the value of the entities in which Plaintiff claims entitlement to a 10% interest, and Plaintiff's multiple claims for punitive damages, the Court finds that Defendants have demonstrated by a preponderance of the evidence that the amount in controversy in this action exceeds $75,000, exclusive of interest and costs. Accordingly, Plaintiff's Motion to Remand (Doc. 7) is due to be denied.
As set forth above, Defendant American Vascular filed a Motion to Transfer this action to the Middle District of Florida pursuant to 28 U.S.C. Section 1404(a). Defendant argues that the parties to this action agreed in a December 30, 2009, Purchase Agreement that venue for any dispute arising out of the agreement would be in St. Petersburg, Florida, which is in the Middle District of Florida, and, further, that this action is due to be transferred to the Middle District of Florida on the basis of forum non conveniens. (Doc. 2 at 1-3). Having reviewed this issue at length, the Court disagrees.
Defendant bases its first argument for transfer on a Forum Selection Clause contained in a Purchase Agreement entered on December 30, 2009, between AVA Mobile Holdings, LLC ("AVAMH")(a non-party to this action), Mobile Vascular Labs, LLC ("MVL") (a non-party to this action), and nine individual doctors (all non-parties to this action). (Doc. 1-1 at 9, 26, 28-30). Notwithstanding American Vascular's repeated representations in its briefs to this Court that it is a party to the Purchase Agreement, the agreement itself places the matter beyond dispute that Defendant American Vascular is neither a signatory nor a party to that agreement.
It is elementary that "[a] third person has no rights under a contract between others unless the contracting parties intend that the third person receive a direct benefit enforceable in court."
Second, Defendant American Vascular argues that this action is due to be transferred to the Middle District of Florida on the basis of forum non conveniens. (Doc. 2 at 3). 28 U.S.C. 1404(a) provides that, "[f]or the convenience of parties and witnesses, in the interest of justice, a district court may transfer any civil action to any other district or division where it might have been brought or to any district or division to which all parties have consented. 28 U.S.C.A. § 1404(a). "District courts have broad discretion in deciding whether to transfer an action to a more convenient forum."
Under the circumstances presented, Defendant's argument that the venue of this action should be moved from this district to the Middle District of Florida is unavailing. First, it is well-settled that the plaintiff's choice of forum (in this case, Vascular Ventures' decision to file suit in a state court found in the Southern District of Alabama) "is entitled to substantial weight and will not lightly be cast aside."
Further, even under a traditional § 1404(a) balancing test, Defendant American Vascular has failed to establish that the proposed new forum is more convenient than Vascular Ventures' selected forum. In this analysis, once it is established that the action could originally have been brought in the proposed transferee forum (which it could have been, inasmuch as a substantial part of the events giving rise to the claim allegedly occurred there),
With respect to witnesses, it does not appear that Alabama is an inconvenient forum, given that many of the witnesses are already in this district, and others are located nearby in an adjacent state. Further, although Defendant argues that two "third-party" witnesses are outside of the forum, one of those witnesses would have to travel from Missouri regardless of which forum was chosen. (Doc. 2 at 4). As to the convenience of the parties, there undoubtedly will be some inconvenience to the defendants attendant to defending themselves in Alabama; however, as the Eleventh Circuit has recognized, "modern methods of transportation and communication have lessened the burden of defending a suit in a foreign jurisdiction."
After careful consideration, based on the totality of the circumstances and the interests of justice, the Court concludes that Defendant American Vascular has not met its heavy burden under § 1404(a) of showing that the desired transferee forum is so much more convenient than Alabama that it should override Plaintiff's choice of forum. In fact, the Court is far from convinced that the Southern District of Alabama is, on balance, any less convenient as a forum for trial than the Middle District of Florida. Accordingly, Defendant's Motion to Transfer Venue (Doc. 2) is due to be denied.
As set forth above, the AVA Affiliates Defendants and the Nominal Defendants filed a Motion to Dismiss for lack of personal jurisdiction pursuant to Rule 12(b)(2), arguing that the Court lacks personal jurisdiction over each of them.
It is well settled that the plaintiff "has the burden of establishing a prima facie case of personal jurisdiction."
In reviewing a challenge to personal jurisdiction, the court must undertake a two-part analysis. The court must evaluate its jurisdiction under the state long-arm statute and then determine whether jurisdiction comports with the Due Process Clause of the Fourteenth Amendment.
The due process inquiry has two requirements. The defendant must have sufficient "minimum contacts" with the forum State.
There are two types of personal jurisdiction: "general" and "specific." There is general personal jurisdiction over a party when "the cause of action does not arise out of . . . the [party's] activities in the forum State," but there are "continuous and systematic" contacts between the two.
In this case, there is no allegation that Defendants have had general contacts with Alabama unrelated to this lawsuit. Thus, the only issue is whether asserting specific personal jurisdiction over these Defendants comports with due process.
For specific personal jurisdiction, the contacts at issue must satisfy the "minimum contacts" test. "Minimum contacts" involve three criteria: First, the contacts must be related to the plaintiff's cause of action or have given rise to it. Second, the contacts must involve some purposeful availment of the privilege of conducting activities within the forum, thereby invoking the benefits and protections of its laws. Finally, the defendant's contacts within the forum state must be such that "[it] should reasonably anticipate being haled into court there."
The minimum contacts analysis is related to the requirement of the Due Process Clause that "individuals have fair warning that a particular activity may subject [them] to the jurisdiction of a foreign sovereign."
Plaintiff filed suit in the Circuit Court of Mobile County, Alabama, against the AVA Affiliates Defendants and the Nominal Defendants on August 9, 2016. (Doc. 1-2). Plaintiff asserts claims against the AVA Affiliates (along with Defendants American Vascular and Dees) for conspiracy (Count Six) and intentional interference with contractual and business relations (AVA Affiliates only) (Counts Seven and Eight). (Doc. 1-2 at 15-19). Plaintiff asserts no claims against the Nominal Defendants. (
Specifically, in Count Six of the complaint, Plaintiff alleges that the Defendant AVA Affiliates are managed and controlled by Defendant Janet Dees; that Defendant American Vascular is managed and controlled by Defendant Janet Dees; that Dees' knowledge of Plaintiff's rights pursuant to the December 30, 2009, incentive agreement is imputed to the AVA Affiliates; and that the AVA Affiliates conspired with Defendants Dees and American Vascular to "fraudulently misrepresent and/or suppress the existence of joint ventures and business opportunities in which Plaintiff was contractually entitled to purchase up to a 10% interest." (Doc. 1-2 at 15-16). In addition, in Counts Seven and Eight, Plaintiff alleges that the "December 30, 2009 incentive agreement constitutes a valid contractual relationship between the Plaintiff and Defendant [American Vascular];" that the AVA Affiliates are not parties to the contractual and business relationship between Plaintiff and Defendant American Vascular; that Janet Dees manages and controls the AVA Affiliates and Defendant American Vascular; that Dees' knowledge of Plaintiff's business relationship with American Vascular and Plaintiff's rights pursuant to the December 30, 2009, incentive agreement are imputed to the AVA Affiliates; and that the AVA Affiliates "intentionally interfered ["for an improper purpose"] with this contract by doing business and entering into contracts and other business arrangements with third-parties, despite having knowledge that the Defendants had breached the December 30, 2009 incentive agreement and that every contract entered into by an AVA Subsidiary violated the terms of the December 30, 2009 agreement." (Doc. 1-2 at 16-19).
The AVA Affiliates and the Nominal Defendants maintain that the Court lacks both general and specific personal jurisdiction over them and that Plaintiff's action against them is, therefore, due to be dismissed. In support of their Motion to Dismiss, Defendants submit the affidavit of Defendant Dees, in which she attests that the AVA Affiliates Defendants (which include AVA Sarasota Holdings, LLC; AVA Newnan Holdings, LLC; AVA Columbus Holdings, LLC; AVA Douglas Holdings, LLC; AVA Saint Louis Holdings, LLC; AVA Valley Holdings LLC; and AVA Duval Holdings, LLC) are all Florida limited liability companies whose members are citizens of either Florida, Ohio, Missouri, or New York.
Plaintiff does not dispute Defendants' evidence but responds that the Court can still assert specific personal jurisdiction over these defendants,
First, with respect to the conspiracy theory of personal jurisdiction, Plaintiff cites
With respect to this theory of personal jurisdiction, the Court need go no further than Plaintiff's allegations regarding the "overt acts" of the conspiracy taken within the forum to dispose of this argument. In the complaint, Plaintiff alleges that Defendants Dees, American Vascular, and the AVA Affiliates conspired to fraudulently misrepresent and/or suppress the existence of future business opportunities by American Vascular in which Plaintiff was contractually entitled to purchase a 10% interest. (Doc. 1-2 at 15-16). According to Plaintiff, future business opportunities arose after December 30, 2009, those being, the formation of the AVA entities named herein as Defendants (i.e., the AVA Affiliates and the Nominal Defendants). (
The problem for Plaintiff lies in the timing of the overt acts of the conspiracy that occurred in Alabama. According to Plaintiff, the overt acts by Dees and American Vascular (which Plaintiff seeks to impute to the AVA Affiliates) occurred on or before December 30, 2009, when Dees and American Vascular contacted Plaintiff and its member doctors in Alabama to negotiate the purchase of the interventional nephrology practice in Mobile, Alabama, on which the December 30, 2009, Purchase Agreement was based. (
Second, with respect to the intentional tort theory of personal jurisdiction, Plaintiff again cites
Defendants argue, however, that those contacts do not exist in the present case and, further, that the mere allegation of an intentional tort that causes injury within a forum is insufficient to establish personal jurisdiction over an out-of-state defendant. The Court agrees.
In
Applying the foregoing authorities to the present case, Plaintiff's allegations of injury alone do not evince a connection between the AVA Affiliates and Alabama and, thus, are insufficient to establish personal jurisdiction over these Defendants, who admittedly have no contacts with the State of Alabama other than Plaintiff's allegations that they intentionally caused injury to Plaintiff in the State of Alabama.
For the foregoing reasons, the AVA Affiliates and the Nominal Defendants' Motion to Dismiss for lack of personal jurisdiction (Doc. 3) is due to be granted.
As set forth above, Defendants American Vascular and Janet Dees have filed a Motion to Dismiss pursuant to Rule 12(b)(6) for failure to state a claim upon which relief can be granted. (Doc. 4 at 1). For the reasons that follow, the Court finds that Defendants' Motion to Dismiss is due to be granted in part and denied in part.
A defendant may move to dismiss a complaint pursuant to Federal Rule of Civil Procedure 12(b)(6) if the plaintiff has failed to state a claim upon which relief may be granted. "The standard of review for a motion to dismiss is the same for the appellate court as it [is] for the trial court."
To survive a 12(b)(6) motion to dismiss for failure to state a claim, the complaint "does not need detailed factual allegations"; however, the "plaintiff's obligation to provide the `grounds' of his `entitle[ment] to relief' requires more than labels and conclusions, and a formulaic recitation of the elements of a cause of action will not do. . . . Factual allegations must be enough to raise a right to relief above the speculative level . . ., on the assumption that all the allegations in the complaint are true (even if doubtful in fact)."
"[U]unsupported conclusions of law or of mixed fact and law" will not defeat a Rule 12(b)(6) motion for dismissal.
As discussed above, Defendants American Vascular and Dees have filed a motion to dismiss for failure to state a claim as to Plaintiff's claims for breach of contract (Count One); Fraud (Counts Two, Three, Four and Five); Conspiracy (Count Six); and Intentional Interference with Contractual and Business Relations (Counts Seven and Eight). The Court will address each of those claims in turn.
In the complaint, Plaintiff alleges that Defendants American Vascular and Janet Dees entered into a contract with Plaintiff Vascular Ventures, LLC, on December 30, 2009; that Vascular Ventures fulfilled it obligations under the agreement; that American Vascular and Dees breached their contractual obligations to offer Vascular Ventures and its doctors an option of purchasing a 10% stake in their future ventures; and that Vascular Ventures has been damaged by American Vascular's and Dees' breaches. (Doc. 1-2 at 10-11). More precisely, Plaintiff alleges in the complaint that, in 2009, Defendants American Vascular and Dees negotiated with Vascular Ventures to buy an interventional nephrology practice in Mobile, Alabama. (
(
In their Motion to Dismiss, Defendants Dees and American Vascular argue that the Purchase Agreement entered on December 30, 2009 (Doc. 1-1 at 9) does not include the Side Letter agreement contained in the letter written by Dees on December 30, 2009; that the Purchase Agreement contains a merger and integration clause prohibiting reference to the Side Letter agreement; and that Plaintiff's complaint fails to state a claim for breach of contract upon which relief can be granted. (Doc. 4 at 7).
Plaintiff Vascular Ventures counters that its breach of contract claim is based on two agreements: (1) the Side Letter agreement, which is a "stand alone" contract between Plaintiff Vascular Ventures and Defendants Dees and American Vascular, and (2) the Side Letter agreement incorporated as an "ancillary agreement" into the Purchase Agreement.
As a preliminary matter, the Court rejects Plaintiff's second argument related to the Purchase Agreement. It is without dispute in this case that the parties to the December 30, 2009, Purchase Agreement are nine individual doctors ("Sellers") (all non-parties to this case), MVL ("Seller") (a non-party to this case), and AVAMH ("Buyer") (a non-party to this case). (Doc. 1-1 at 10, 28-30). Neither Plaintiff nor any Defendant in this case alleges that it is a party or an intended third-party beneficiary to that Purchase Agreement. Therefore, even if the Side Letter agreement were assumed to be a part of the Purchase Agreement, there is no party in this lawsuit who can enforce it, nor is there any party against whom to enforce it.
On the other hand, with respect to Plaintiff's claim that the Side Letter agreement is a stand alone contract between Vascular Ventures, Dees, and American Vascular, the Court agrees that Plaintiff has at least stated a claim against these Defendants for breach of contract as to this agreement. "In the ordinary breach of contract action, the claimant must prove: (1) the existence of a valid contract binding the parties in the action, (2) his own performance under the contract, (3) the defendant's nonperformance, and (4) damages."
The Side Letter document shows an executed, binding agreement signed by Dees, ostensibly on behalf of American Vascular, to reserve a minimum of 10% of American Vascular's future business ventures for investment by Vascular Ventures and its doctor members, in exchange for which Plaintiff/its doctor members would sell 40% of MVL to American Vascular's affiliate, AVAMH.
Plaintiff further alleges that it performed its obligations under the agreement; that Defendants breached their obligations under the agreement by failing to offer Plaintiff and its member doctors the opportunity to invest in their future ventures; and that Plaintiff was damaged thereby. (Doc. 1-2 at 6-11). Plaintiff's allegations satisfy the elements of a breach of contract claim in Alabama based on the Side Letter agreement.
The Court rejects Defendant Dees' argument that her Motion to Dismiss should be granted because she signed the Side Letter agreement only on behalf of American Vascular. The document itself is unclear as to the precise capacity in which Dees was signing and, thus, that issue will be have to be resolved at a later stage of this litigation. For now, Plaintiff's allegations are sufficient to state a claim for breach of the Side Letter agreement by both Defendant Dees and Defendant American Vascular.
Accordingly, Defendants Dees and American Vascular's Motion to Dismiss Plaintiff's breach of contract claim (Count One) based on the December 30, 2009, Purchase Agreement is due to be granted, and Defendants' Motion to Dismiss Plaintiff's breach of contract claim based on the stand alone Side Letter agreement is due to be denied.
In the motion to dismiss and accompanying brief, Defendants move to dismiss Plaintiff's fraud claims (Counts Two-Five) for failure to state a claim upon which relief can be granted. (Doc. 4 at 8-15). Because Plaintiff alleges fraud, the substantive allegations in the complaint must comply not only with the plausibility criteria articulated in
Rule 9(b) requires that "[i]n alleging fraud or mistake, a party must state with particularity the circumstances constituting fraud or mistake." Fed. R. Civ. P. 9(b). Under Rule 9(b), a plaintiff must allege: "(1) the precise statements, documents, or misrepresentations made; (2) the time, place, and person responsible for the statement; (3) the content and manner in which these statements misled the Plaintiffs; and (4) what the defendants gained by the alleged fraud."
"Rule 9(b)'s heightened pleading standard may be applied less stringently . . . when specific `factual information [about the fraud] is peculiarly within the defendant's knowledge or control.'"
The Court now turns to Plaintiff's fraud claims in the present case.
In Count Two of the complaint, Plaintiff alleges "Negligent/Reckless Misrepresentation" against Defendant Janet Dees and Defendant American Vascular, stating: "[o]n or around December 30, 2009, Defendants Janet R. Dees and [American Vascular] negligently or recklessly made a false representation that they would offer Plaintiff Vascular Ventures, LLC and the doctors of Plaintiff Vascular Ventures, LLC the option to purchase up to a 10% interest in all future joint ventures and business opportunities arising out of Defendant [American Vascular's] general course of business;" in reliance on this misrepresentation, Plaintiff and its member physicians were induced to sell 40% of MVL to American Vascular; Plaintiff's reliance was reasonable as there was no reason to believe that Defendants would not fulfill their "promise;" and Plaintiff was damaged thereby. (Doc. 1-2 at 11-12) (emphasis added).
The elements of the tort of fraudulent misrepresentation are (1) a false representation (2) regarding a material existing fact, (3) which the plaintiff relies upon, and (4) damages proximately caused by the misrepresentation.
In the present case, Plaintiff alleges that Defendants Dees and American Vascular promised that they would offer Plaintiff the option of purchasing up to a 10% interest in all future joint ventures arising out of American Vascular's general course of business. Clearly, these allegations sound in promissory fraud, not misrepresentation of an existing material fact. Indeed, Plaintiff concedes in its brief that its claim sounds more in promissory fraud than in fraudulent misrepresentation. (Doc. 13 at 17 n.7).
Accordingly, Defendants Dees and American Vascular's Motion to Dismiss Plaintiff's Negligent/Reckless Misrepresentation (Count Two) is due to be granted.
In Count Three, Plaintiff expressly alleges a claim for "Promissory Fraud" against Defendants Dees and American Vascular, restating: "[o]n or around March 11, 2009 and December 30, 2009, Defendants Janet R. Dees and [American Vascular] made a false representation that they would offer Plaintiff Vascular Ventures, LLC and the doctors of Plaintiff Vascular Ventures, LLC the option to purchase up to a 10% interest in all future joint ventures and business opportunities arising out of Defendant [American Vascular's] general course of business;" "[a]t the time the representation was made, Defendants Janet R. Dees and [American Vascular] had no intention of providing Plaintiff with any option to buy into such future business opportunities;" Plaintiff reasonably relied on the misrepresentation and its members were induced by this representation to sell 40% of MVL to American Vascular; there was no reason to believe that Defendants would fail to fulfill their promise; and Plaintiff was damaged thereby. (Doc. 1-2 at 12-13).
As discussed, these allegations of fraud based on the promise to do something in the future clearly sound in promissory fraud. When asserting a claim for promissory fraud, "[t]he burden is on the plaintiff to prove that when the promise was made the defendant intended to deceive."
In the present case, Plaintiff alleges that, despite Defendants' promise to offer Plaintiff and its member doctors the opportunity to invest up to 10% in "all future joint ventures and business opportunities arising out of [American Vascular's] general course of business" (Doc. 1-2 at 12), Defendants Dees and American Vascular formed approximately fourteen new businesses, i.e., the entities referred to herein as the AVA Affiliates and the Nominal Defendants, without including Plaintiff or its member doctors as investors in a single venture. (Doc. 1-2 at 7-9). Thus, Plaintiff alleges, on approximately fourteen separate occasions, one of which was only five weeks after the agreement/promise was made,
Accordingly, Defendant Dees and American Vascular's Motion to Dismiss Plaintiff's promissory fraud claim (Count Three) is due to be denied.
In Count Four of the complaint, Plaintiff alleges "Fraudulent Suppression" against Dees and American Vascular, stating: "[s]tarting December 30, 2009, Defendants Janet R. Dees and [American Vascular] had a duty to disclose all future joint ventures or business opportunities arising out of Defendant [American Vascular's] general course of business;" "[s]ince December 30, 2009, Defendants Janet R. Dees and [American Vascular] have failed to disclose material facts about future joint ventures and business opportunities that have arisen out of [American Vascular's] general course of business;" and Plaintiff has been damaged thereby. (Doc. 1-2 at 13-14).
When asserting a claim for fraudulent suppression, Plaintiff must allege that: "(1)[t]he defendant had a duty to disclose an existing material fact; (2) the defendant concealed or suppressed that material fact; (3) the defendant's suppression induced the plaintiff to act or refrain from acting; and (4) the plaintiff suffered actual damage as a proximate result."
Plaintiff has alleged that, after December 30, 2009, Defendants failed to disclose/suppressed the fact that they were forming new entities (i.e., the AVA Affiliates and Nominal Defendants), ventures in which Plaintiff was entitled to invest and about which Defendants had a duty to disclose based on its December 30, 2009, agreement with Plaintiff. (Doc. 1-2 at 13). However, Plaintiff has not alleged facts showing that, after December 30, 2009, Defendants' suppression induced Plaintiff to act or refrain from acting.
Accordingly, Defendants' Motion to Dismiss Plaintiff's fraudulent suppression claim (Count Four) is due to be granted.
In Count Five of the complaint, Plaintiff alleges "Fraud in the Inducement" against Defendants Dees and American Vascular, stating: "[o]n or around December 30, 2009, Defendants Janet R. Dees and [American Vascular] made a false representation that they would offer Plaintiff Vascular Ventures, LLC and the doctors of Plaintiff Vascular Ventures, LLC the option to purchase up to a 10% interest in all future joint ventures and business opportunities arising out of Defendant [American Vascular's] general course of business;" [a]t the time the representation was made, Defendants Janet R. Dees and [American Vascular] had no intention of providing Plaintiff with any option to buy into such future business opportunities;" Plaintiff reasonably relied on this false representation and was induced to sell 40% of MVL to American Vascular; Plaintiff's reliance was reasonable because there was no reason to believe that Defendants would fail to fulfill their promise; and Plaintiff was damaged thereby. (Doc. 1-2 at 14-15).
"Fraud in the inducement consists of one party's misrepresenting a material fact concerning the subject matter of the underlying transaction and the other party's relying on the misrepresentation to his, her, or its detriment in executing a document or taking a course of action."
The Alabama Supreme Court has stated that, "[t]he only basis upon which one may recover for fraud, where the alleged fraud is predicated on a promise to perform or abstain from some act in the future . . . is when the evidence shows that, at the time of the promises of future action or abstention were made, the promisor had no intention of carrying out the promises, but rather had a present intent to deceive."
Having already found that Plaintiff's fraud allegations based on Defendants' promise of future action sound in promissory fraud, Defendants Dees and American Vascular's Motion to Dismiss Plaintiff's claim for fraud in the inducement (Count Five) is due to be granted.
In the complaint, Plaintiff alleges that Defendants, the AVA Affiliates, Dees, and American Vascular conspired to fraudulently misrepresent and/or suppress the existence of joint ventures and business opportunities in which Plaintiff was entitled to purchase up to a 10% interest and that Plaintiff was damaged thereby. (Doc. 1-2 at 15-16). Having already found that the AVA Affiliates Defendants are due to be dismissed from this case for lack of personal jurisdiction, it is unnecessary to discuss them further.
Turning now to Plaintiff's allegations of conspiracy against Defendants Dees and American Vascular, it is well settled that "Alabama recognizes civil conspiracy as a substantive tort."
In the present case, Plaintiff alleges that Defendants Dees and American Vascular agreed to do something unlawful, i.e., commit fraud, in order to prevent Plaintiff from knowing about, and taking advantage of, investment opportunities that Defendants created after December 30, 2009, in which Plaintiff was entitled to invest. Plaintiff further alleges that it was damaged by this conspiracy. (Doc. 1-2 at 15-16). Based on these allegations, the Court finds that Plaintiff has stated a claim for civil conspiracy.
Accordingly, Defendants Dees and American Vascular's motion to dismiss Plaintiff's civil conspiracy claim (Count Six) is due to be denied.
Last, Plaintiff alleges that the AVA Affiliates Defendants intentionally interfered with its business and contractual relations with Defendant American Vascular. (Doc. 1-2 at 16-19). Having found that the Court lacks personal jurisdiction over the AVA Affiliates Defendants, Plaintiff's claims (Counts Seven and Eight) are due to be dismissed.
For the reasons discussed herein, the undersigned hereby RECOMMENDS that Plaintiff's Motion to Remand (Doc. 7) is due to be DENIED; that Defendant American Vascular's Motion to Transfer Venue (Doc. 2) is due to be DENIED; that the AVA Affiliates and Nominal Defendants' Motion to Dismiss for lack of personal jurisdiction (Doc. 3) is due to be GRANTED; and that Defendants Dees and American Vascular's Motion to Dismiss for failure to state a claim (Doc. 4) is due to be GRANTED IN PART AND DENIED IN PART as follows:
(Count One) Breach of Contract — Defendants' Motion to Dismiss Plaintiff's breach of contract claim based on the Purchase Agreement is due to be GRANTED, and Defendants' Motion to Dismiss Plaintiff's breach of contract claim based on the Side Letter Agreement is due to be DENIED;
(Count Two) Defendants' Motion to Dismiss Plaintiff's negligent/reckless misrepresentation claim is due to be GRANTED;
(Count Three) Defendants' Motion to Dismiss Plaintiff's promissory fraud claim (Count Three) is due to be DENIED;
(Count Four) Defendants' Motion to Dismiss Plaintiff's fraudulent suppression claim (Count Four) is due to be GRANTED;
(Count Five) Defendants' Motion to Dismiss Plaintiff's fraud in the inducement claim is due to be GRANTED;
(Count Six) Defendants' Motion to Dismiss Plaintiff's civil conspiracy claim is due to be DENIED;
(Counts Seven and Eight) Defendants' Motion to Dismiss Plaintiff's claims for intentional interference with business and contractual relations (Counts Seven and Eight) is due to be GRANTED.
A copy of this report and recommendation shall be served on all parties in the manner provided by law. Any party who objects to this recommendation or anything in it must, within fourteen (14) days of the date of service of this document, file specific written objections with the Clerk of this Court. See 28 U.S.C. § 636(b)(1); Fed. R. Civ. P. 72(b); S.D. ALA. GenLR 72(c). The parties should note that under Eleventh Circuit Rule 3-1, "[a] party failing to object to a magistrate judge's findings or recommendations contained in a report and recommendation in accordance with the provisions of
Ala. R. Civ. P. 4.2(b) (Effective August 1, 2004).